Contineum Therapeutics (CTNM) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kamada (KMDA) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 13.7% versus a gain of 8.4%. Contineum Therapeutics is the larger company by market cap ($495.8 million vs $448.7 million), about 1.1 times the size. Kamada pays a dividend yielding 3.22%, while Contineum Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | KMDA |
|---|---|---|
| Share price | $13.18 | $7.78 |
| Market cap | $495.85M | $448.70M |
| 1-day change | +3.53% | -1.46% |
| YTD return | +15.31% | +10.13% |
| 1-year return | +8.39% | +13.67% |
| 5-year return | — | +47.53% |
| P/E ratio (TTM) | — | 20.46 |
| Forward P/E | — | 13.48 |
| EPS (TTM) | $-1.73 | $0.38 |
| Dividend yield | 0.00% | 3.22% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $17.79 | $9.35 |
| 52-week low | $8.60 | $6.55 |
| Distance from 52-week high | -25.89% | -16.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.18% | +73.63% |
| Average volume | 516.85K | 118.61K |
| Shares outstanding | 32.96M | 57.71M |
| Employees | 51 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
CTNM vs KMDA FAQ
Which is bigger, Contineum Therapeutics or Kamada?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $495.85M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, CTNM or KMDA?
KMDA returned +13.67% over the past 12 months, compared with +8.39% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Contineum Therapeutics or Kamada?
Kamada pays a dividend yielding 3.22%, while Contineum Therapeutics does not currently pay a regular dividend.
Are Contineum Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.